Dr Sekowska Leczenie Bolu
- Address
- ul. Wolnosc 2, lok. 5U-80, 01-018 Warsaw, Poland
Immune System Diseases at Dr Sekowska Leczenie Bolu
The site is conducting clinical research in immune system diseases, focusing on conditions such as moderate to severe atopic dermatitis, moderate to severe chronic spontaneous urticaria, and alopecia areata. These studies are designed to assess new treatment options and compare them with placebo to better understand symptom control and disease improvement.
- Atopic dermatitis treatment effectiveness
- Chronic spontaneous urticaria symptom control
- Alopecia areata hair regrowth research
This research aims to improve care for patients with inflammatory and immune-related skin conditions by evaluating whether new therapies can offer better relief and visible clinical benefit.
Nervous System Diseases
Clinical trials at this Warsaw site also address nervous system diseases, with a strong emphasis on migraine and related headache disorders, including migraine attacks with or without aura and menstrual migraine. The research is centered on finding better ways to prevent attacks and improve short-term relief for people living with frequent migraines.
- Migraine prevention strategies
- Acute migraine treatment
- Menstrual migraine prevention
These studies are evaluating whether newer therapies can reduce migraine burden, improve pain relief, and support patients who have not responded well to standard preventive medicines.
Skin and Connective Tissue Diseases
The research portfolio at Dr Sekowska Leczenie Bolu includes trials in skin and connective tissue diseases, especially conditions that affect daily comfort, appearance, and quality of life. The main focus is on testing therapies that may ease inflammation, reduce symptoms, and improve visible skin outcomes.
- Atopic dermatitis inflammation relief
- Urticaria management
- Skin disease treatment evaluation
Overall, the site contributes to clinical studies that aim to refine treatment choices for chronic dermatologic conditions and support better long-term disease control.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dr Sekowska Leczenie Bolu
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Phase 3 Double-Blind Study on Rimegepant for Intermittent Prevention of Menstrual Migraine in Women Aged 18-45 | Pfizer Inc. | Phase III | Not Recruiting | Oct 2025 | — |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rimegepant | 1 | Unknown | 2025-10-17 | 2025-10-17 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
